PRAX
Praxis Precision Medicines
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Praxis Precision Medicines received FDA Breakthrough Therapy Designation for elsunersen in SCN2A-related developmental and epileptic encephalopathyJun 22, 2026
- Praxis announced FDA acceptance of NDA for ulixacaltamide in essential tremorApr 14, 2026
- FDA grants Breakthrough Therapy Designation to Praxis' ulixacaltamide for essential tremorDec 29, 2025
- Praxis Precision Medicines plans NDA filing in early 2026 for Relutrigine in SCN2A/SCN8A developmental epileptic encephalopathiesDec 11, 2025
- Praxis Precision Medicines aligns with FDA on simplified and accelerated registrational pathway for Elsunersen in early-onset SCN2A developmental and epileptic encephalopathyDec 10, 2025